177 related articles for article (PubMed ID: 23121278)
1. Safety of pharmacoenhancers for HIV therapy.
von Hentig N; Haberl A
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):557-68. PubMed ID: 23121278
[TBL] [Abstract][Full Text] [Related]
2. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
[TBL] [Abstract][Full Text] [Related]
3. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
Marzolini C; Gibbons S; Khoo S; Back D
J Antimicrob Chemother; 2016 Jul; 71(7):1755-8. PubMed ID: 26945713
[TBL] [Abstract][Full Text] [Related]
4. Cobicistat, a pharmacoenhancer for HIV treatments.
Temesgen Z
Drugs Today (Barc); 2013 Apr; 49(4):233-7. PubMed ID: 23616950
[TBL] [Abstract][Full Text] [Related]
5. Atazanavir/ritonavir: a review of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers.
Kakuda TN; Opsomer M; Timmers M; Iterbeke K; Van De Casteele T; Hillewaert V; Petrovic R; Hoetelmans RM
J Clin Pharmacol; 2014 Aug; 54(8):949-57. PubMed ID: 24644095
[TBL] [Abstract][Full Text] [Related]
7. Darunavir/cobicistat once daily for the treatment of HIV.
Kakuda TN; Crauwels H; Opsomer M; Tomaka F; van de Casteele T; Vanveggel S; Iterbeke K; de Smedt G
Expert Rev Anti Infect Ther; 2015 Jun; 13(6):691-704. PubMed ID: 25962100
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat.
Renjifo B; van Wyk J; Salem AH; Bow D; Ng J; Norton M
AIDS Rev; 2015; 17(1):37-46. PubMed ID: 25586481
[TBL] [Abstract][Full Text] [Related]
10. Interaction involving tadalafil and CYP3A4 inhibition by ritonavir.
Loulergue P; Gaillard R; Mir O
Scand J Infect Dis; 2011 Mar; 43(3):239-40. PubMed ID: 20942777
[No Abstract] [Full Text] [Related]
11. Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy.
von Hentig N
HIV AIDS (Auckl); 2016; 8():1-16. PubMed ID: 26730211
[TBL] [Abstract][Full Text] [Related]
12. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.
Putcharoen O; Do T; Avihingsanon A; Ruxrungtham K
Drug Des Devel Ther; 2015; 9():5763-9. PubMed ID: 26566368
[TBL] [Abstract][Full Text] [Related]
13. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection.
Shah BM; Schafer JJ; Priano J; Squires KE
Pharmacotherapy; 2013 Oct; 33(10):1107-16. PubMed ID: 23471741
[TBL] [Abstract][Full Text] [Related]
14. Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C; Tribut O
Drugs; 2005; 65(5):633-59. PubMed ID: 15748098
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
16. Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
van Heeswijk RP; Veldkamp A; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
Antivir Ther; 2001 Dec; 6(4):201-29. PubMed ID: 11878403
[TBL] [Abstract][Full Text] [Related]
17. Drug interactions. Amprenavir with low-dose ritonavir.
TreatmentUpdate; 2006; 18(3):9-10. PubMed ID: 17211921
[No Abstract] [Full Text] [Related]
18. Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection.
Temesgen Z
Drugs Today (Barc); 2012 Dec; 48(12):765-71. PubMed ID: 23243633
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic enhancers in HIV therapeutics.
Larson KB; Wang K; Delille C; Otofokun I; Acosta EP
Clin Pharmacokinet; 2014 Oct; 53(10):865-72. PubMed ID: 25164142
[TBL] [Abstract][Full Text] [Related]
20. Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients.
Nadler JP; Gathe JC; Pollard RB; Richmond GJ; Liao Q; Griffith S; Lancaster CT; Hernandez JE; Pappa KA;
BMC Infect Dis; 2003 Jun; 3():10. PubMed ID: 12795812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
